Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) was downgraded by equity researchers from StockNews.com from a “strong buy” rating to a “buy” rating in a research report released Thursday.
Several other analysts have also recently commented on FMS. Societe Generale reduced its price target on Fresenius Medical Care AG & Co. KGaA from €61.00 ($64.21) to €57.00 ($60.00) in a Friday, February 25 research note. Berenberg Bank lowered its price target on Fresenius Medical Care AG & Co. KGaA from €84.90 ($89.37) to €83.40 ($87.79) in a Thursday, March 17 research report. JPMorgan Chase & Co. raised its price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($51.26) to €51.00 ($53.68) and assigned the stock a “underweight” rating in a Thursday, May 5, research report. Oddo Bhf upgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperforming” rating and set a target price of €72.00 ($75.79) on the stock in a report research on Tuesday, March 1. Finally, Truist Financial lowered its price target on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a research report Wednesday. Two research analysts rated the stock with a sell rating, six gave the company a hold rating and four gave the company a buy rating. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $52.09.
FMS rose $0.24 on Thursday, hitting $24.17. 1,228,796 shares of the company were traded, against an average volume of 550,739. The company has a 50-day moving average of $29.61 and a 200-day moving average of $31.61. The company has a quick ratio of 0.93, a current ratio of 1.26 and a leverage ratio of 0.51. The stock has a market capitalization of $14.16 billion, a PE ratio of 13.81, a PEG ratio of 0.98 and a beta of 1.17. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $23.29 and a 12-month high of $42.13.
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) last released its quarterly earnings data on Wednesday, May 4. The company reported EPS of $0.38 for the quarter, beating the consensus estimate of $0.30 by $0.08. The company posted revenue of $5.10 billion in the quarter, versus a consensus estimate of $4.97 billion. Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 6.99% and a net margin of 4.91%. On average, research analysts expect Fresenius Medical Care AG & Co. KGaA to post EPS of 1.93 for the current year.
Several institutional investors and hedge funds have recently increased or reduced their stake in the stock. Bank of America Corp DE increased its equity stake in Fresenius Medical Care AG & Co. KGaA by 27.9% in Q1. Bank of America Corp DE now owns 1,083,689 shares of the company worth $36,499,000 after acquiring an additional 236,459 shares during the period. Royal Bank of Canada increased its holdings of Fresenius Medical Care AG & Co. KGaA shares by 6.4% in Q1. Royal Bank of Canada now owns 245,214 shares of the company worth $8,259,000 after acquiring an additional 14,686 shares during the period. First Republic Investment Management Inc. acquired a new stake in Fresenius Medical Care AG & Co. KGaA during Q1 valued at $207,000. Guardian Capital Advisors LP increased its stake in Fresenius Medical Care AG & Co. KGaA by 10.7% during the 1st quarter. Guardian Capital Advisors LP now owns 52,148 shares of the company valued at $1,744,000 after buying an additional 5,045 shares in the last quarter. Finally, Wetherby Asset Management Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 9.0% in the 1st quarter. Wetherby Asset Management Inc. now owns 6,807 shares of the company valued at $229,000 after purchasing an additional 560 shares in the last quarter. Institutional investors and hedge funds own 4.73% of the company’s shares.
About Fresenius Medical Care AG & Co. KGaA (Get a rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Fresenius Medical Care AG & Co. KGaA right now?
Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.
While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here